Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 All nodes lead to chemo...

× No keyword cloud information.

15 in total

1. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.

Authors: P M Ravdin; I A Siminoff; J A Harvey
Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544

2. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

Authors: Nancy E Davidson; Anne M O'Neill; Allen M Vukov; C Kent Osborne; Silvana Martino; Douglas R White; Martin D Abeloff
Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544

3. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

Authors:
Journal: N Engl J Med Date: 1988-12-29 Impact factor: 91.245

4. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

Authors:
Journal: J Natl Cancer Inst Date: 2007-04-04 Impact factor: 13.506

5. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.

Authors: David A L Morgan; Nicholas A Refalo; Kwok Leung Cheung
Journal: Breast Date: 2010-12-14 Impact factor: 4.380

6. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?

Authors: V M Duric; M R Stockler; S Heritier; F Boyle; J Beith; A Sullivan; N Wilcken; A S Coates; R J Simes
Journal: Ann Oncol Date: 2005-08-26 Impact factor: 32.976

7. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors:
Journal: Lancet Date: 2005 May 14-20 Impact factor: 79.321

8. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Authors: J Cuzick; L Ambroisine; N Davidson; R Jakesz; M Kaufmann; M Regan; R Sainsbury
Journal: Lancet Date: 2007-05-19 Impact factor: 79.321

9. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.

Authors: Beat Thürlimann; Karen N Price; Richard D Gelber; Stig B Holmberg; Diana Crivellari; Marco Colleoni; John Collins; John F Forbes; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal: Breast Cancer Res Treat Date: 2008-02-08 Impact factor: 4.872

10. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

Authors: S J Jansen; J Kievit; M A Nooij; J C de Haes; I M Overpelt; H van Slooten; E Maartense; A M Stiggelbout
Journal: Br J Cancer Date: 2001-06-15 Impact factor: 7.640

1 in total

1. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.

Authors: Daniel J Farrugia; Alessandra Landmann; Li Zhu; Emilia J Diego; Ronald R Johnson; Marguerite Bonaventura; Atilla Soran; David J Dabbs; Beth Z Clark; Shannon L Puhalla; Rachel C Jankowitz; Adam M Brufsky; Barry C Lembersky; Gretchen M Ahrendt; Priscilla F McAuliffe; Rohit Bhargava
Journal: Mod Pathol Date: 2017-05-26 Impact factor: 7.842

1 in total